Can a natural compound slow Alzheimer's decline?

NCT ID NCT07066826

NEW Recruiting now Disease control Sponsor: Wanbangde Pharmaceutical Group Co., LTD Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial is testing whether huperzine A, given as a controlled-release tablet, can improve thinking and daily living skills in people with mild-to-moderate Alzheimer's dementia. Participants will receive either huperzine A, a placebo, or an existing Alzheimer's drug (donepezil) to compare effects. The study aims to see if huperzine A is safe and effective, and whether it might offer a new way to manage symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Huperzine A controlled-release tablets
What this could lead to: If successful, this could provide a new treatment option to help slow cognitive decline and preserve daily functioning in people with mild-to-moderate Alzheimer's dementia.
What could go wrong: This is an early-to-mid-stage trial, so results may not confirm benefit or safety. The study compares against placebo and an existing drug, and long-term effects are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DEMENTIA

Contacts and locations

Locations

Xuanwu Hospital Capital Medical University
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.